Compare Prologis Inc (PLD) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prologis Inc vs TG Therapeutics Inc — how do they compare? Prologis Inc trades at $129.49 (market cap $122.87B), while TG Therapeutics Inc trades at $55.14 (market cap $8.16B). The key difference: Prologis Inc is far larger — about 15.1× TG Therapeutics Inc's market cap, and Prologis Inc pays a 3.31% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Prologis Inc for 102 Days and TG Therapeutics Inc for 16 Days on average.
| PLD | TGTX | |
|---|---|---|
Market Cap | $122.87B | $8.16B |
Volume | 4,222,957 | 1,735,121 |
Sector | Real Estate | Health |
52-Week High | $149.96 | $59.06 |
52-Week Low | $111.23 | $26.94 |
Typical Hold Time | 102 Days | 16 Days |
Enterprise Value | $157.61B | $8.37B |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PLD trades at $129.49, up 1.72% today, with a bearish technical signal from moving averages but strong fundamentals including a 45.79% net income margin and three consecutive quarterly earnings beats. The stock is supported by robust leasing activity and data center growth, as highlighted in recent CFO commentary (Defense World, 2026-09-21).
The outlook is positive with a consensus price target of $155.15 (59.52% buy ratings), but risks include rising debt-to-asset ratio (37.2% in 2025) and market volatility. Upside is driven by warehouse demand and data center expansion, while macroeconomic headwinds pose challenges.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
